Clinical Trial: Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).
Study Status: Completed
Recruit Status: RECRUITING
Condition: Liver Cirrhosis
Study Type: INTERVENTIONAL
Official Title: Evaluation of Prolonged-release Pirfenidone in Patients With Viral C Hepatitis, With Sustained Viral Response and Advanced Residual Liver Fibrosis. Potential Role of Epigenetics to Understand Therapeu
Brief Summary:
Prolonged-Release Pirfenidone (PR-PFD) is an anti-fibrogenic and anti-inflammatory molecule used for the treatment of idiopathic pulmonary fibrosis (approved by FDA) and liver fibrosis (approved in Mexico by COFEPRIS).PFD effects are mediated in part through inhibition of TGF?, TNF?, IL-1 and IL-6, along with NF?B activation down-regulation causing reduced TNF? and IFN? levels.The aim of this protocol is to know if the epigenetic factors induced by PR-PFD have a regulatory role to understand the progression…
Read more